Want to see RDHL full AI Analyst Report?
RDHL Stock Chart & Stats
$1.20
-$0.32(-4.91%)
At close: 4:00 PM EST
$1.20
-$0.32(-4.91%)
Day’s Range― - ―
52-Week Range$0.63 - $2.79
Previous CloseN/A
Volume5.64K
Average Volume (3M)1.98M
Market Cap
$3.95M
Enterprise Value$0.69
Total Cash (Recent Filing)$2.87M
Total Debt (Recent Filing)$214.00K
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding6,080,920
10 Day Avg. Volume104,605
30 Day Avg. Volume1,981,143
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.76
Price to Sales (P/S)11.38
P/FCF Ratio-0.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)$50.60M
Bulls Say, Bears Say
Bulls Say
Regulatory Incentives For OpaganibThe rare pediatric disease designation creates potential regulatory and commercial advantages (e.g., Priority Review Voucher eligibility) for opaganib in neuroblastoma. That status strengthens long-term development economics and de-risks part of the oncology pipeline if clinical benefits are confirmed.
Biodefense And Antiviral PositioningPositioning opaganib as an oral antiviral for Ebola and outbreak response leverages existing clinical and preclinical evidence plus past BARDA recognition. This creates durable strategic optionality: government partnerships, stockpiling or emergency use pathways can provide non-commercial revenue and long-term program support.
Next‑generation Crohn's Asset (RHB‑204)RHB-204's comparable MAP efficacy at lower doses suggests an improved therapeutic index versus its predecessor. A focused Phase 2 in MAP-positive patients builds on prior Phase 3 success and patent protection, offering sustained upside if it provides an oral, differentiated option in a growing Crohn's market with high unmet need.
Bears Say
Sharp Revenue DeclineThe steep top-line collapse materially weakens durable commercial cash flows and undermines the company's ability to self-fund development. Absent reliable product sales or licensed revenue, program timelines and commercialization plans become contingent on external financing or asset sales, increasing execution risk.
Persistent Negative Operating Cash FlowSustained multi-year cash burn shows the business is not generating sufficient internal cash to fund operations or trials. This structural cash deficit forces recurring capital raises, constrains strategic flexibility, and heightens the risk that development programs could be delayed or scaled back if financing conditions tighten.
Ongoing Reliance On Dilutive FinancingRepeated private placements, expanded ATM capacity and long‑dated warrants signal dependence on equity markets to fund operations and acquisitions. That creates persistent dilution risk and can limit management's ability to plan multiyear programs without the specter of further fundraising, impacting shareholder alignment and capital structure.
RedHill Biopharma News
RDHL FAQ
What was RedHill Biopharma’s price range in the past 12 months?
RedHill Biopharma lowest stock price was $0.63 and its highest was $2.79 in the past 12 months.
What is RedHill Biopharma’s market cap?
RedHill Biopharma’s market cap is $3.95M.
When is RedHill Biopharma’s upcoming earnings report date?
RedHill Biopharma’s upcoming earnings report date is Aug 20, 2026 which is in 15 days.
How were RedHill Biopharma’s earnings last quarter?
Currently, no data Available
Is RedHill Biopharma overvalued?
According to Wall Street analysts RedHill Biopharma’s price is currently Overvalued.
Does RedHill Biopharma pay dividends?
RedHill Biopharma does not currently pay dividends.
What is RedHill Biopharma’s EPS estimate?
RedHill Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RedHill Biopharma have?
RedHill Biopharma has 6,080,920 shares outstanding.
What happened to RedHill Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of RedHill Biopharma?
Currently, no hedge funds are holding shares in RDHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RedHill Biopharma
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Technical Analysis
China Pharma Holdings
―
Sonoma Pharmaceuticals
―
PainReform
―
Universe Pharmaceuticals
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
― Insiders
―
Mutual Funds
9.25% Other Institutional Investors
90.75% Public Companies and
Individual Investors